NEW YORK — PredxBio on Wednesday announced a collaboration with University of Queensland researcher Arutha Kulasinghe aimed at developing a spatial-biomarker-based companion diagnostic for immunotherapy response prediction.
Kulasinghe, who leads the Queensland Spatial Biology Center (QSBC), will present a study jointly conducted with PredxBio at the Society for Immunotherapy of Cancer (SITC) 2024 Conference next month. Using PredxBio's SpaceIQ platform, the study assessed spatial intratumoral heterogeneity in non-small cell lung cancer, with a focus on immunometabolic pathways and their role in immunotherapy response.
Pittsburgh-based PredxBio is developing cancer therapeutics using artificial intelligence-driven spatial biomarkers that explore the mechanisms of drug actions and predict patient outcomes with high accuracy. Its SpaceIQ platform reveals "critical" spatial biomarker, allowing for the development of predictive biomarkers for companion diagnostics.
"The collaborations with leading spatial biology investigators and top-tier institutions make [UQ and QSBC] the ideal [partners] to help us accelerate the translation of spatial biology into clinical practice," PredxBio CEO Dusty Majumdar said in a statement. "Together, we aim to impact the lives of countless cancer patients through more precise diagnostics and targeted therapies."